11:18 AM EST - Optimi Health : Is celebrating the launch of Blue Serenity, Canada’s first natural therapeutic psilocybin product, in collaboration with psilocybin patient advocate Thomas Hartle. Once approved by health authorities under Canada’s Special Access Program or an authorized clinical trial, patients, doctors, and researchers will receive Blue Serenity in blister packs of eight psilocybin capsules. Blue Serenity is packaged according to current regulations and guidelines governing the manufacture and commercial distribution of medical/pharmaceutical products. Optimi Health
shares C.OPTI are trading up $0.03 at $0.41.
